Loading data for VTRS — first visit, this takes a few seconds.

Viatris Inc. (VTRS)

NasdaqGS: VTRS · Real-Time Price · USD

16.51

+0.13 (0.79%)

At close: Sep 11, 2026, 3:59 PM

16.45

-0.36%

After-hours: 7:30 PM

Alert

The price, the headline numbers and the latest news, in one place.

0.79% (1D)

Bid	15.21
Market Cap	19B
Revenue (ttm)	14.7B
Net Income (ttm)	-411M
	0.88
	-0.37
	n/a
	6.21
P/B (ttm)	1.31
P/S (ttm)	1.29
Earnings Date	Nov 5, 2026

Ask	17.86
Volume	12,173,962
Avg. Volume (20D)	9,591,114
Open	16.50
Previous Close	16.38
Day's Range	16.32 - 16.65
52-Week Range	9.43 - 18.39
Analyst	n/a
Price Target	n/a
Dividends	$0.48 (2.93%)
Ex-Dividend Date	Aug 21, 2026

About VTRS

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various ther...

Sector Healthcare

IPO Date Mar 17, 1980

Employees 30,000

Stock Exchange NasdaqGS

Ticker Symbol VTRS

Website https://www.viatris.com

Full Company Profile

Financial Performance

In 2025, Viatris's revenue was 14.3B, a decrease of -2.98% compared to the previous year's 14.74B. Earnings were -3.51B, an increase of 454.23%.

Financial Statements

Earnings Surprise

Viatris has released their quarterly earnings on Aug 6, 2026:

Revenue of $3.76B misses estimates by $0, with 4.88% YoY growth.
EPS of 0.69 exceeds estimates by 0.09, with 11.29% YoY growth.

Next Earnings Release

Viatris Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

1 week ago · Insider Monkey

Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks

The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We r...

1 week ago · Zacks

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris

Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.

1 week ago · StockStory

3 Cash-Producing Stocks That Concern Us

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

2 weeks ago · Simply Wall St.

Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?

Why recent generic drug earnings matter for Viatris stock Recent earnings across the generic drug industry highlighted steady demand alongside pricing and supply challenges, putting fresh attention on...

2 weeks ago · Proactive

Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US...

Page 1 of 2